Figures & data
Figure 1. Cisplatin-repressed cell proliferation and accelerated cell apoptosis in MGC-803 and MGC-803/DDP cells. MGC-803 and MGC-803/DDP cells were treated by 0, 10, 20, 30, 40, 50 µg/mL of cisplatin for 48 h respectively. (a) Cell viability was tested by CCK-8 assay. ** denotes p < 0.01 and *** denotes p < 0.001 vs. the MGC-803 group. MGC-803 and MGC-803/DDP cells were treated by 30 µg/mL of cisplatin. (b) Cell apoptotic rate was measured by apoptosis assay, (c-f) the levels of Bax, cleaved-caspase-3, and cleaved-PARP protein were tested by western blot. *** denotes p < 0.001 vs. control (Ctrl) group.
Figure 2. Lido reduced cisplatin resistance in MGC-803/DDP cells. MGC-803/DDP cells were treated by 0, 25, 50, 100, 200 µM of Lido for 24 h. (a) Cell viability was tested by CCK-8 assay. MGC-803/DDP cells was treated by cisplatin (0, 10, 20, 30, 40, 50 µg/mL) alone for 48 h or in combination with Lido (100 µM). (b) Cell viability was tested by CCK-8 assay. ** denotes p < 0.01 and *** denotes p < 0.001 vs. MGC-803/DDP + cisplatin group. MGC-803/DDP cells were treated by cisplatin (30 µg/mL) and Lido (100 µM) or only cisplatin (30 µg/mL). (c) Cell apoptotic rate was measured by apoptosis assay, (d-e) Bax, cleaved-caspase-3, and cleaved-PARP protein levels in were tested by western blot. ** denotes p < 0.01 and *** denotes p < 0.001 vs. control (Ctrl) group. ## denotes p < 0.01 and ### denotes p < 0.001 vs. cisplatin group.
Figure 3. Lido suppressed the migration and invasion of MGC-803/DDP cells. MGC-803/DDP cells were treated by 100 µM of Lido for 24 h. (a) The rate of cell migration was determined by migration assay, (b) the rate of cell invasion was determined by invasion assay, (c-d) MMP-2, MMP-9 and TIMP-1 protein levels were measured by western blot. ** denotes p < 0.01 and *** denotes p < 0.001 vs. control (Ctrl) group.
Figure 4. Lido inhibited miR-10b level in MGC-803/DDP cells. (a) The expression levels of miR-10b in MGC-803 and MGC-803/DDP cells were determined by qRT-PCR. *** denotes p < 0.001 vs. the MGC-803. (b) MGC-803/DDP cells were treated 100 µM of Lido for 24 h, and then miR-10b expression levels were determined by qRT-PCR. *** denotes p < 0.001 vs. control (Ctrl) group.
Figure 5. Lido reduced cisplatin resistance in MGC-803/DDP cells through down-regulating miR-10b expression. NC mimic and miR-10b mimic were transfected in MGC-803/DDP cells for 48 h. (a) MiR-10b expression levels were determined by qRT-PCR. ### denotes p < 0.001 vs. NC mimic group. After transfection with NC mimic or miR-10b mimic, MGC-803/DDP cells were treated by cisplatin (30 µg/mL) in combination with Lido (100 µM). (b) Cell viability was determined by CCK-8 assay, (c) cell apoptotic rate was determined by apoptosis assay, (d-e) Bax, cleaved-caspase-3, and cleaved-PARP protein expression levels were determined by western blot. *** indicates p < 0.001 vs. control (Ctrl) group. ### denotes p < 0.001 vs. cisplatin group. ^ denotes p < 0.05 and ^^^ denotes p < 0.001 vs. cisplatin + Lido + NC mimic group.
Figure 6. Lido repressed AKT/mTOR and β-catenin pathways via down-regulating miR-10b level. After transfection with NC mimic or miR-10b mimic, MGC-803/DDP cells were treated by cisplatin (30 µg/mL) in combination with Lido (100 µM). (a-b) The phosphorylation levels of AKT and mTOR were determined by western blot, (c-d) the β-catenin levels were also determined by western blot. * denotes p < 0.05 and *** denotes p < 0.001 vs. control (Ctrl) group. # denotes p < 0.05 and ### denotes p < 0.001 vs. cisplatin group. ^ denotes p < 0.05 and ^^^ denotes p < 0.001 vs. cisplatin + Lido + NC mimic group.
Data availability statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.